Advanced or metastatic clear cell RCC select phase 3 clinical trials in the first- and second-line settings

Authored by Toni Choueiri, published on 2026-04-16 07:42:23.0

Selected phase 3 clinical trials in progress in the first- and second-line settings for advanced or metastatic clear cell RCC patients. (A) Design of the MK-6482-012 trial (NCT04736706) in the first-line setting, looking at pembrolizumab/lenvatinib in two triplet combinations with either a quavonlimab co-formulation or belzutifan versus standard of care. (B) Design of the Alliance-A031704/PDIGREE trial (NCT03793166) in the first-line setting, looking at a risk-adapted approach after induction treatment withnivolumab/ipilimumab. (C) Design of the LITESPARK-011 trial (NCT04586231) in the second- and third-line settings or after neoadjuvant or adjuvanttreatment, including a combination of belzutifan/lenvatinib in comparison to cabozantinib as monotherapy. IMDC = International Metastatic RCC Database Consortium; KPS = Karnofsky performance score; R = randomization; RCC = renal cell carcinoma; CR = complete response; PD = progressive disease.First and Second-line Treatments in Metastatic Renal Cell Carcinoma, European Urology, Volume 87, Issue 2, 2025, Pages 143-154, https://doi.org/10.1016/j.eururo.2024.10.019.